Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct 1;10(10):CD012963.
doi: 10.1002/14651858.CD012963.pub2.

Prostanoids and their analogues for the treatment of pulmonary hypertension in neonates

Binoy Shivanna  1 , Sharada Gowda, Stephen E Welty, Keith J Barrington, Mohan Pammi
Affiliations
Review

Prostanoids and their analogues for the treatment of pulmonary hypertension in neonates

Binoy Shivanna et al. Cochrane Database Syst Rev. .

Abstract

Background: Persistent pulmonary hypertension of the newborn (PPHN) is a disease entity that describes a physiology in which there is persistence of increased pulmonary arterial pressure. PPHN is characterised by failure to adapt to a functional postnatal circulation with a fall in pulmonary vascular resistance. PPHN is responsible for impairment in oxygenation and significant neonatal mortality and morbidity. Prostanoids and their analogues may be useful therapeutic interventions due to their pulmonary vasodilatory and immunomodulatory effects.

Objectives: Primary objective• To determine the efficacy and safety of prostanoids and their analogues (iloprost, treprostinil, and beraprost) in decreasing mortality and the need for extracorporeal membrane oxygenation (ECMO) among neonates with PHSecondary objective• To determine the efficacy and safety of prostanoids and their analogues (iloprost, treprostinil, and beraprost) in decreasing neonatal morbidity (necrotizing enterocolitis (NEC), chronic lung disease (CLD), retinopathy of prematurity (ROP), intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), length of hospital stay, and duration of mechanical ventilation) and improving neurodevelopmental outcomes among neonates with PHComparisons• Prostanoids and their analogues at any dosage or duration used to treat PPHN versus 'standard treatment without these agents', placebo, or inhaled nitric oxide (iNO) therapy• Prostanoids and their analogues at any dosage or duration used to treat refractory PPHN as an 'add-on' therapy to iNO versus iNO alone SEARCH METHODS: We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 9), MEDLINE via PubMed (1966 to 16 September 2018), Embase (1980 to 16 September 2018), and the Cumulative Index to Nursing and Allied Health Literature (CINAHL; 1982 to 16 September 2018). We also searched clinical trials databases, conference proceedings of the Pediatric Academic Societies (1990 to 16 September 2018), and the reference lists of retrieved articles for randomized controlled trials and quasi-randomized trials. We contacted authors who have published in this field as discerned from the reference lists of identified clinical trials and review authors' personal files.

Selection criteria: Randomized and quasi-randomized controlled trials evaluating prostanoids or their analogues (at any dose, route of administration, or duration) used in neonates at any gestational age less than 28 days' postnatal age for confirmed or suspected PPHN.

Data collection and analysis: We used the standard methods of Cochrane Neonatal to conduct a systematic review and to assess the methodological quality of included studies (neonatal.cochrane.org/en/index.html). Three review authors independently assessed the titles and abstracts of studies identified by the search strategy and obtained full-text versions for assessment if necessary. We designed forms for trial inclusion or exclusion and for data extraction. We planned to use the GRADE approach to assess the quality of evidence.

Main results: We did not identify any eligible neonatal trials evaluating prostanoids or their analogues as sole agents in the treatment of PPHN.

Authors' conclusions: Implications for practiceCurrently, no evidence shows the use of prostanoids or their analogues as pulmonary vasodilators and sole therapeutic agents for the treatment of PPHN in neonates (age 28 days or less).Implications for researchThe safety and efficacy of different preparations and doses and routes of administration of prostacyclins and their analogues in neonates must be established. Well-designed, adequately powered, randomized, multi-center trials are needed to address the efficacy and safety of prostanoids and their analogues in the treatment of PPHN. These trials should evaluate long-term neurodevelopmental and pulmonary outcomes, in addition to short-term outcomes.

PubMed Disclaimer

Conflict of interest statement

BS has no known conflicts of interest. SG has no known conflicts of interest. SW has no known conflicts of interest. KB has no known conflicts of interest. MP has no known conflicts of interest.

Update of

References

References to studies excluded from this review

Ahmad 2018 {published data only}
    1. Ahmad KA, Banales J, Henderson CL, Ramos SE, Brandt KM, Powers GC. Intravenous epoprostenol improves oxygenation index in patients with persistent pulmonary hypertension of the newborn refractory to nitric oxide. Journal of Perinatology 2018 Sep;38(9):1212‐9. - PubMed
Carpentier 2017 {published data only}
    1. Carpentier E, Mur S, Aubry E, Pognon L, Rakza T, Flamein F, et al. Safety and tolerability of subcutaneous treprostinil in newborns with congenital diaphragmatic hernia and life‐threatening pulmonary hypertension. Journal of Pediatric Surgery 2017;52(9):1480‐3. - PubMed
Eifinger 2008 {published data only}
    1. Eifinger F, Sreeram N, Mehler K, Huenseler C, Kribs A, Roth B. Aerosolized iloprost in the treatment of pulmonary hypertension in extremely preterm infants: a pilot study. Klinische Padiatrie 2008;220(2):66‐9. - PubMed
Eronen 1997 {published data only}
    1. Eronen M, Pohjavuori M, Andersson S, Pesonen E, Raivio KO. Prostacyclin treatment for persistent pulmonary hypertension of the newborn. Pediatric Cardiology 1997;18(1):3‐7. - PubMed
Kelly 2002 {published data only}
    1. Kelly LK, Porta NF, Goodman DM, Carroll CL, Steinhorn RH. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. Journal of Pediatrics 2002;141(6):830‐2. [PUBMED: 12461501] - PubMed
Nakwan 2011 {published data only}
    1. Nakwan N, Nakwan N, Wannaro J. Persistent pulmonary hypertension of the newborn successfully treated with beraprost sodium: a retrospective chart review. Neonatology 2011;99(1):32‐7. - PubMed
Olson 2015 {published data only}
    1. Olson E, Lusk LA, Fineman JR, Robertson L, Keller RL. Short‐term treprostinil use in infants with congenital diaphragmatic hernia following repair. Journal of Pediatrics 2015;167(3):762‐4. - PMC - PubMed
Park 2017 {published data only}
    1. Park BY, Chung SH. Treprostinil for persistent pulmonary hypertension of the newborn, with early onset sepsis in preterm infant: 2 case reports. Medicine (Baltimore) 2017;96(26):e7303. - PMC - PubMed
Shiyanagi 2008 {published data only}
    1. Shiyanagi S, Okazaki T, Shoji H, Shimizu T, Tanaka T, Takeda S, et al. Management of pulmonary hypertension in congenital diaphragmatic hernia: nitric oxide with prostaglandin‐E1 versus nitric oxide alone. Pediatric Surgery International 2008;24(10):1101‐4. - PubMed
Sood 2014 {published data only}
    1. Sood BG, Keszler M, Garg M, Klein JM, Ohls R, Ambalavanan N, et al. for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Inhaled PGE1 in neonates with hypoxemic respiratory failure: two pilot feasibility randomized clinical trials. Trials 2014;15:486. - PMC - PubMed
Yilmaz 2014 {published data only}
    1. Yilmaz O, Kahveci H, Zeybek C, Ciftel M, Kilic O. Inhaled iloprost in preterm infants with severe respiratory distress syndrome and pulmonary hypertension. American Journal of Perinatology 2014;31(4):321‐6. - PubMed

Additional references

Barst 1994
    1. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long‐term continuous intravenous prostacyclin. Annals of Internal Medicine 1994;121(6):409‐15. [PUBMED: 8053614] - PubMed
Barst 1996
    1. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. New England Journal of Medicine 1996;334(5):296‐301. [DOI: 10.1056/NEJM199602013340504; PUBMED: 8532025] - DOI - PubMed
Barst 1999
    1. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999;99(9):1197‐208. - PubMed
Bell 1978
    1. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Annals of Surgery 1978;187(1):1‐7. [PUBMED: 413500] - PMC - PubMed
Bhat 2012
    1. Bhat R, Salas AA, Foster C, Carlo WA, Ambalavanan N. Prospective analysis of pulmonary hypertension in extremely low birth weight infants. Pediatrics 2012;129(3):e682‐9. [DOI: 10.1542/peds.2011-1827; PUBMED: 22311993] - DOI - PMC - PubMed
Bos 1993
    1. Bos AP, Tibboel D, Koot VC, Hazebroek FW, Molenaar JC. Persistent pulmonary hypertension in high‐risk congenital diaphragmatic hernia patients: incidence and vasodilator therapy. Journal of Pediatric Surgery 1993;28(11):1463‐5. [PUBMED: 8301459] - PubMed
Cabral 2013
    1. Cabral JE, Belik J. Persistent pulmonary hypertension of the newborn: recent advances in pathophysiology and treatment. Jornal de Pediatria 2013;89(3):226‐42. [DOI: 10.1016/j.jped.2012.11.009; PUBMED: 23684454] - DOI - PubMed
CCRP 1984
    1. Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Archives of Ophthalmology 1984;102(8):1130‐4. [PUBMED: 6547831] - PubMed
Chotigeat 2007
    1. Chotigeat U, Jaratwashirakul S. Inhaled iloprost for severe persistent pulmonary hypertension of the newborn. Journal of the Medical Association of Thailand 2007;90(1):167‐70. [PUBMED: 17621749] - PubMed
Christman 1992
    1. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. New England Journal of Medicine 1992;327(2):70‐5. [DOI: 10.1056/NEJM199207093270202; PUBMED: 1603138] - DOI - PubMed
Cornfield 1992
    1. Cornfield DN, Chatfield BA, McQueston JA, McMurtry IF, Abman SH. Effects of birth‐related stimuli on L‐arginine‐dependent pulmonary vasodilation in ovine fetus. American Journal of Physiology 1992;262(5 Pt 2):H1474‐81. [DOI: 10.1152/ajpheart.1992.262.5.H1474; PUBMED: 1590451] - DOI - PubMed
De Luca 2007
    1. Luca D, Zecca E, Piastra M, Romagnoli C. Iloprost as 'rescue' therapy for pulmonary hypertension of the neonate. Paediatric Anaesthesia 2007;17(4):394‐5. [DOI: 10.1111/j.1460-9592.2006.02104.x; PUBMED: 17359413] - DOI - PubMed
Doran 2008
    1. Doran AK, Ivy DD, Barst RJ, Hill N, Murali S, Benza RL. Guidelines for the prevention of central venous catheter‐related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. International Journal of Clinical Practice. Supplement 2008;160:5‐9. [DOI: 10.1111/j.1742-1241.2008.01811.x; PUBMED: 18638170] - DOI - PMC - PubMed
Dorris 2012
    1. Dorris SL, Peebles RS Jr. PGI2 as a regulator of inflammatory diseases. Mediators of Inflammation 2012;2012:926968. [DOI: 10.1155/2012/926968; PUBMED: 22851816] - DOI - PMC - PubMed
Ehlen 2003
    1. Ehlen M, Wiebe B. Iloprost in persistent pulmonary hypertension of the newborn. Cardiology in the Young 2003;13(4):361‐3. [PUBMED: 14694957] - PubMed
ELSO 2013
    1. Extracorporeal Life Support Organization (ELSO). Guidelines for neonatal respiratory failure. www.elso.org/Portals/0/IGD/Archive/FileManager/8588d1a580cusersshyerdocu... 2013; Vol. Version 1.3. - PubMed
Ewert 2009
    1. Ewert R, Schäper C, Halank M, Gläser S, Opitz CF. Inhalative iloprost ‐ pharmacology and clinical application. Expert Opinion on Pharmacotherapy 2009;10(13):2195‐207. [DOI: 10.1517/14656560903164228; PUBMED: 19663611] - DOI - PubMed
Gomberg‐Maitland 2008
    1. Gomberg‐Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. European Respiratory Journal 2008;31(4):891‐901. [DOI: 10.1183/09031936.00097107; PUBMED: 18378784] - DOI - PubMed
GRADEpro GDT 2015 [Computer program]
    1. McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed prior to 12 December 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
Higgins 2011
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Ivy 2007
    1. Ivy DD, Claussen L, Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. American Journal of Cardiology 2007;99(5):696‐8. [DOI: 10.1016/j.amjcard.2006.09.119; PUBMED: 17317374] - DOI - PMC - PubMed
Ivy 2008
    1. Ivy DD, Doran AK, Smith KJ, Mallory GB Jr, Beghetti M, Barst RJ, et al. Short‐ and long‐term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. Journal of the American College of Cardiology 2008;51(2):161‐9. [DOI: 10.1016/j.jacc.2007.09.031; PUBMED: 18191742] - DOI - PMC - PubMed
Ivy 2010
    1. Ivy DD. Prostacyclin in the intensive care setting. Pediatric Critical Care Medicine 2010;11(2 Suppl):S41‐5. [DOI: 10.1097/PCC.0b013e3181d10845; PUBMED: 20216163] - DOI - PMC - PubMed
Ivy 2013
    1. Ivy DD, Abman SH, Barst RJ, Berger RM, Bonnet D, Fleming TR, et al. Pediatric pulmonary hypertension. Journal of the American College of Cardiology 2013;62(25 Suppl):D117‐26. [DOI: 10.1016/j.jacc.2013.10.028; PUBMED: 24355636] - DOI - PubMed
Janjindamal 2013
    1. Janjindamai W, Thatrimontrichai A, Maneenil G, Chanvitan P, Dissaneevate S. Effectiveness and safety of intravenous iloprost for severe persistent pulmonary hypertension of the newborn. Indian Pediatrics 2013;50:934‐8. - PubMed
Jobe 2001
    1. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. American Journal of Respiratory and Critical Care Medicine 2001;163(7):1723‐9. [DOI: 10.1164/ajrccm.163.7.2011060; PUBMED: 11401896] - DOI - PubMed
Jones 1997
    1. Jones RL, Qian Y, Wong HN, Chan H, Yim AP. Prostanoid action on the human pulmonary vascular system. Clinical and Experimental Pharmacology and Physiology 1997;24(12):969‐72. [PUBMED: 9406667] - PubMed
Keller 2016
    1. Keller RL. Pulmonary hypertension and pulmonary vasodilators. Clinics in Perinatology 2016;43(1):187‐202. [DOI: 10.1016/j.clp.2015.11.013; PUBMED: 26876130] - DOI - PubMed
Kelly 2017
    1. Kelly LE, Ohlsson A, Shah PS. Sildenafil for pulmonary hypertension in neonates. The Cochrane Database of Systematic Reviews 2017, Issue CD005494. - PMC - PubMed
Koch 2000
    1. Koch JA, Plum J, Grabensee B, Modder U, PGE1 Study Group. Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media?. Nephrology, Dialysis, Transplantation 2000;15:43‐9. - PubMed
Lakshminrusimha 1999
    1. Lakshminrusimha S, Steinhorn RH. Pulmonary vascular biology during neonatal transition. Clinics in Perinatology 1999;26(3):601‐19. [PUBMED: 10494467] - PubMed
Lakshminrusimha 2012
    1. Lakshminrusimha S. The pulmonary circulation in neonatal respiratory failure. Clinics in Perinatology 2012;39(3):655‐83. [DOI: 10.1016/j.clp.2012.06.006; PUBMED: 22954275] - DOI - PMC - PubMed
Lakshminrusimha 2016
    1. Lakshminrusimha S, Mathew B, Leach CL. Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide. Seminars in Perinatology 2016;40:160‐73. - PMC - PubMed
Levy 2011
    1. Levy M, Celermajer DS, Bourges‐Petit E, Cerro MJ, Bajolle F, Bonnet D. Add‐on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension. Journal of Pediatrics 2011;158(4):584‐8. [DOI: 10.1016/j.jpeds.2010.09.025; PUBMED: 21035821] - DOI - PubMed
Majed 2012
    1. Majed BH, Khalil RA. Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. Pharmacological Reviews 2012;64(3):540‐82. [DOI: 10.1124/pr.111.004770; PUBMED: 22679221] - DOI - PMC - PubMed
McNulty 1993
    1. McNulty MJ, Sailstad JM, Steffen RP. The pharmacokinetics and pharmacodynamics of the prostacyclin analog 15AU81 in the anesthetized beagle dog. Prostaglandins, Leukotrienes & Essential Fatty Acids 1993;48(2):159‐66. [PUBMED: 8446654] - PubMed
Mourani 2008
    1. Mourani PM, Sontag MK, Younoszai A, Ivy DD, Abman SH. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. Pediatrics 2008;121(2):317‐25. [DOI: 10.1542/peds.2007-1583; PUBMED: 18245423] - DOI - PMC - PubMed
Mourani 2015
    1. Mourani PM, Sontag MK, Younoszai A, Miller JI, Kinsella JP, Baker CD, et al. Early pulmonary vascular disease in preterm infants at risk for bronchopulmonary dysplasia. American Journal of Respiratory and Critical Care Medicine 2015;191(1):87‐95. - PMC - PubMed
Nakayama 2007
    1. Nakayama T, Shimada H, Takatsuki S, Hoshida H, Ishikita T, Matsuura H, et al. Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japenese children. Circulation Journal 2007;71(11):1785‐90. [PUBMED: 17965503] - PubMed
Nuntnarumit 1999
    1. Nuntnarumit P, Yang W, Bada‐Ellzey HS. Blood pressure measurements in the newborn. Clinics in Perinatology 1999;26(4):981‐96. [PUBMED: 10572732] - PubMed
Olschewski 2004
    1. Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A, et al. Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacology & Therapeutics 2004;102(2):139‐53. [DOI: 10.1016/j.pharmthera.2004.01.003; PUBMED: 15163595] - DOI - PubMed
Papile 1978
    1. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. Journal of Pediatrics 1978;92(4):529‐34. [PUBMED: 305471] - PubMed
Payne 2013
    1. Payne AH, Hintz SR, Hibbs AM, Walsh MC, Vohr BR, Bann CM, et al. Neurodevelopmental outcomes of extremely low‐gestational‐age neonates with low‐grade periventricular‐intraventricular hemorrhage. JAMA Pediatrics 2013;167(5):451‐9. [PUBMED: 23460139] - PMC - PubMed
Pedersen 2018
    1. Pedersen J, Hedegaard ER, Simonsen U, Kruger M, Infanger M, Grimm D. Current and future treatments for persistent pulmonary hypertension in the newborn. Basic & Clinical Pharmacology & Toxicology 2018;123:392‐406. - PubMed
Porta 2012
    1. Porta NF, Steinhorn RH. Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents. Clinics in Perinatology 2012;39(1):149‐64. [DOI: 10.1016/j.clp.2011.12.006; PUBMED: 22341543] - DOI - PMC - PubMed
Putensen 1998
    1. Putensen C, Hormann C, Kleinsasser A, Putensen‐Himmer G. Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine 1998;157(6 Pt 1):1743‐7. [DOI: 10.1164/ajrccm.157.6.9609017; PUBMED: 9620900] - DOI - PubMed
Read 1985
    1. Read NG, Radomski MW, Goodwin DA, Moncada S. An ultrastructural study of stored human platelets after washing using prostacyclin. British Journal of Haematology 1985;60(2):305‐14. [PUBMED: 3890933] - PubMed
RevMan 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rosenzweig 1999
    1. Rosenzweig EB, Kerstein D, Barst RJ. Long‐term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99(14):1858‐65. [PUBMED: 10199883] - PubMed
Rubin 1990
    1. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Annals of Internal Medicine 1990;112(7):485‐91. [PUBMED: 2107780] - PubMed
Saji 2016
    1. Saji T, Myoishi M, Sugimura K, Tahara N, Takeda Y, Fukuda K, et al. Efficacy and safety of inhaled iloprost in Japanese patients with pulmonary arterial hypertension ‐ Insights from the IBUKI and AIR studies. Circulation 2016;80:835‐42. - PubMed
Schünemann 2013
    1. Schünemann H, Brożek J, Guyatt G, Oxman A, editor(s). GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Updated October 2013. Available from gdt.gradepro.org/app/handbook/handbook.html (accessed 22 October 2018).
Sitbon 2002
    1. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, et al. Long‐term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. Journal of the American College of Cardiology 2002;40(4):780‐8. [PUBMED: 12204511] - PubMed
Sood 2004
    1. Sood BG, Delaney‐Black V, Aranda JV, Shankaran S. Aerosolized PGE1: a selective pulmonary vasodilator in neonatal hypoxemic respiratory failure results of a Phase I/II open label clinical trial. Pediatr Research 2004;56(4):579‐85. [DOI: 10.1203/01.PDR.0000139927.86617.B6; PUBMED: 15295081] - DOI - PMC - PubMed
Steinhorn 2012
    1. Steinhorn RH. Pharmacotherapy for pulmonary hypertension. Pediatric Clinics of North America 2012;59(5):1129‐46. [DOI: 10.1016/j.pcl.2012.07.011; PUBMED: 23036248] - DOI - PMC - PubMed
Storme 2013
    1. Storme L, Aubry E, Rakza T, Houeijeh A, Debarge V, Tourneux P, et al. Pathophysiology of persistent pulmonary hypertension of the newborn: impact of the perinatal environment. Archives of Cardiovascular Diseases 2013;106(3):169‐77. [DOI: 10.1016/j.acvd.2012.12.005; PUBMED: 23582679] - DOI - PubMed
Tapson 2013
    1. Tapson VF, Jing ZC, Xu KF, Pan L, Feldman J, Kiely DG, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM‐C2 study): a randomized controlled trial. Chest 2013;144:952‐8. - PubMed
Teitel 1990
    1. Teitel DF, Iwamoto HS, Rudolph AM. Changes in the pulmonary circulation during birth‐related events. Pediatric Research 1990;27(4 Pt 1):372‐8. [DOI: 10.1203/00006450-199004000-00010; PUBMED: 2342829] - DOI - PubMed
Vane 1995
    1. Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. American Journal of Cardiology 1995;75(3):3A‐10A. [PUBMED: 7840052] - PubMed
Vane 2003
    1. Vane J, Corin RE. Prostacyclin: a vascular mediator. European Journal of Vascular and Endovascular Surgery 2003;26(6):571‐8. [PUBMED: 14603414] - PubMed
Volpe 2008
    1. Volpe JJ. Neurology of the Newborn. 5th Edition. Philadelphia: WB Saunders, 2008:347‐99.
Walsh‐Sukys 2000
    1. Walsh‐Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000;105(1 Pt 1):14‐20. [PUBMED: 10617698] - PubMed
Wharton 2000
    1. Wharton J, Davie N, Upton PD, Yacoub MH, Polak JM, Morrell NW. Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation 2000;102(25):3130‐6. [PUBMED: 11120706] - PubMed
Yung 2004
    1. Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004;110(6):660‐5. [DOI: 10.1161/01.CIR.0000138104.83366.E9; PUBMED: 15289375] - DOI - PubMed